Respiratory syncytial virus (RSV) cases are on the rise in the United States, leading to an increasing number of children being hospitalized across the country, according to the latest update from the Centers for Disease Control and Prevention. This trend highlights the importance of preventive measures to combat the spread of the virus.

A recent study published in November 2024 demonstrated the effectiveness of a newly approved vaccine, nirsevimab, in reducing hospitalizations in non-immunocompromised individuals aged 60 and older. Phase 3 trial data released in the fall also showed promising results, with nirsevimab cutting RSV hospitalizations in healthy infants by 77%. These findings offer hope for better protection against RSV, which is a significant cause of mortality in children under 5 years old worldwide.

Nirsevimab, approved by the Food and Drug Administration in July 2023, is a long-acting monoclonal antibody designed to prevent RSV-associated lower respiratory tract infections in infants and young children. Unlike traditional vaccines that stimulate the body to produce antibodies, nirsevimab provides passive immunization by delivering pre-formed antibodies through a jab.

The CDC’s Advisory Committee on Immunization Practices recommended nirsevimab for infants under eight months of age to safeguard against severe RSV infections during their first RSV season. Children between eight and 19 months old who are at higher risk for severe RSV disease were also advised to receive the vaccine. The committee’s decision was based on data showing that nirsevimab is 90% effective in preventing hospitalizations in infants under 8 months old.

In countries like the United Kingdom and France, where nirsevimab has been in use, there has been a notable decrease in hospital admissions related to RSV. However, the absence of nirsevimab in certain regions, coupled with high RSV incidence, can strain hospital resources, as seen in the Netherlands, where pediatric ICUs are facing a surge in cases. The Dutch government’s Health Council has recommended offering nirsevimab to all infants in the country to mitigate the impact of RSV.

As the fight against RSV continues, the availability and widespread administration of vaccines like nirsevimab play a crucial role in protecting vulnerable populations, especially young children, from the severe effects of the virus. By staying informed and following public health recommendations, we can work together to reduce the burden of RSV and safeguard the health of our communities.